EUVIMEDEUVIMED entdecken
Crossref

PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ

Simon F Roy iD, Gauri Panse iD, Jennifer M McNiff

Journal of Cutaneous Pathology · 2023

DOI: 10.1111/cup.14407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2023. Verfasst von Simon F Roy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Immunohistochemistry, Keratosis, Actinic, Lichenoid Eruptions, Melanoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Distinguishing melanocytic pseudonests encountered in lichenoid dermatoses or lichenoid keratoses from melanoma in situ (MIS) with brisk lichenoid inflammation can prove challenging.

Methods

We designed a case–control study to evaluate the accuracy metrics of PRAME immunohistochemistry to distinguish melanocytic pseudonests in lichenoid dermatoses or keratoses from inflamed MIS. Immunostaining for PRAME was performed on paraffin‐embedded formalin‐fixed diagnostic tissue using a rabbit monoclonal antibody to PRAME (Abcam), with a 1:3200 dilution on a Leica Bond detection system.

Results

Our search identified 21 cases of melanocytic pseudonests ( n = 21, 46%) encountered in lichenoid dermatoses and 24 cases of inflamed MIS ( n = 24, 53%). Each method of evaluating PRAME immunohistochemistry (PRAME+ clusters, PRAME % of melanocytes by four categories and PRAME+ melanocyte counts per linear mm of epidermal basal layer) showed statistically significant differences between the MIS and the pseudonest cohorts (respectively, p < 0.001; p < 0.001; and p < 0.001). Receiver operating characteristics analysis for PRAME+ melanocyte counts per linear mm of epidermal basal layer revealed an area under the curve of 0.9 ± 0.05 (95% confidence interval 0.9–1.0). When determining an optimal cut‐off point for the best Youden index [sensitivity (%) + specificity (%) − 100], the cut‐off of 1.0 PRAME+ melanocytes per linear mm showed a sensitivity of 79.2% and specificity of 85.7% (Youden index 0.65) to distinguish MIS from pseudonests.

Conclusion

PRAME immunohistochemistry may constitute an additional tool for this challenging differential diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunohistochemistryKeratosis, ActinicLichenoid EruptionsMelanomaSkin NeoplasmsHumansAntigens, NeoplasmCase-Control StudiesDiagnosis, DifferentialMelanocytesCutaneous Malignant Melanoma

Stichwörter der Autor:innen

PRAMEcase-control studylichen planus-like keratosislichenoid dermatosesmelanocytic pseudonestspreferentially expressed antigen in melanomapseudomelanocytic nests

Substanzen

Antigens, NeoplasmPRAME protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Simon F Roy, Gauri Panse

Zitieren

APA

Roy, S. F., Panse, G., & McNiff, J. M. (2023). PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14407

Vancouver

Roy SF, Panse G, McNiff JM. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ. Journal of Cutaneous Pathology. 2023. doi:10.1111/cup.14407

BibTeX
@article{Roy2023,
  author = {Roy, Simon F and Panse, Gauri and McNiff, Jennifer M},
  title = {PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ},
  journal = {Journal of Cutaneous Pathology},
  year = {2023},
  doi = {10.1111/cup.14407}
}
Kostenlos starten →